REFERENCES

  1. Sonis, S. T. (2004) Oral mucositis in cancer therapy. J Support Oncology, 2(3):3–8.
  2. Trotti, A., Bellm, L. A., Epstein, J. B., et al. (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 66(3):253–262.
  3. Wardley, A. M., Jayson, G. C., Swindell, R., et al. (2000) Prospective evaluation of OM in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol, 110(2):292–299.
  4. Fulton, J. S., Middleton, G. J., McPhail, J. T. (2002) Management of oral complications. Semin Oncol Nurs, 18(1):28–35.
  5. Dodd, M. J., Miaskowski, C., Dibble, S. L., et al. (2000) Factors influencing OM in patients receiving chemotherapy. Cancer Pract, 8(6):291–297.
  6. Vera-Llonch, M., Oster, G., et al. (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer, 106(2):329–336.
  7. Bruce, S. D., Quinn, A. (2007) US Oncological Disease, 1:86–90.
  8. Barauskas, J., Christerson, L., Wadsäter, M., et al, (2014) Bioadhesive Lipid Compositions: Self-Assembly Structures, Functionality, and Medical Applications. Mol. Pharmaceutics, 11(3):895−903.
  9. Camurus. (2015) episil® package leaflet.
  10. Seidenspinner, I., Adamietz, I. A., Strohm, G. L. and Tiberg, T. (2015) Effects of episil® oral liquid in cancer patients with oral mucositis: an observational study. Poster presented at MASCC, 2015.
  11. Hadjieva, T., Cavallin-Ståhl, E., Linden, M. and Tiberg, F. (2014) Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer, 22(6):1557–1562.
  12. Patent EP1848403. Topical Bioadhesive Formulations.
  13. Svanberg, A., Birgegård, G., Öhrn, K. (2010) A new preventive strategy using a bioadhesive oromucosal lipid solution and oral cryotherapy to protect the oral cavity and reduce the need for total parenteral nutrition (TPN) for patients undergoing autologous stemcell transplantation. Support Care Cancer, 18, (Suppl. 3) S114.